Comparative Pharmacology
Head-to-head clinical analysis: METHYLPREDNISOLONE versus STERI STAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYLPREDNISOLONE versus STERI STAT.
METHYLPREDNISOLONE vs STERI-STAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; inhibits phospholipase A2, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and immune cell activity.
Binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by blocking peptide bond formation and translocation.
4-48 mg/day orally in divided doses; 10-40 mg IV/IM bolus, then 10-40 mg IV q4-6h; high-dose IV pulse: 1 g/day for 3 days.
Adults: 1 gram intravenously every 8 hours infused over 60 minutes.
None Documented
None Documented
Plasma: 2.5-3.5 hours; biological half-life (tissue): 18-36 hours due to glucocorticoid receptor-mediated effects; clinical context: anti-inflammatory effects persist beyond plasma clearance
Clinical Note
moderateMethylprednisolone + Digoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethylprednisolone + Digitoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethylprednisolone + Deslanoside
"Methylprednisolone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMethylprednisolone + Acetyldigitoxin
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal (primarily as inactive metabolites, <10% unchanged); minor biliary/fecal elimination
Renal excretion of unchanged drug accounts for approximately 95% of elimination; biliary/fecal elimination is minimal (<5%).
Category D/X
Category C
Corticosteroid
Corticosteroid
"Methylprednisolone may decrease the cardiotoxic activities of Acetyldigitoxin."